For most healthy adults, serum beta-2 microglobulin (B2M) falls somewhere between about 1.0 and 2.4 mg/L, though the exact cutoffs vary by laboratory and by age. A large study of adults over 40 reported a reference range of 0.95 to 2.73 mg/L, with the upper end climbing steadily in older age groups. That single number on your lab report carries a surprising amount of diagnostic weight: B2M is used to stage blood cancers, track kidney function, monitor autoimmune disease activity, and even flag infections in the central nervous system. Understanding where the “normal” boundaries sit and why they shift is the first step to making sense of an abnormal result.
What Beta-2 Microglobulin Actually Is
B2M is a small protein found on the surface of nearly every cell in your body that has a nucleus. It forms part of the major histocompatibility complex (MHC) class I molecule, the structure your immune system uses to present pieces of foreign invaders to T cells so they can be identified and attacked.1PubMed. beta 2-Microglobulin: structure, function and significance Because cells constantly shed and replace these surface molecules, a steady trickle of B2M enters the bloodstream at all times. From there, it passes through the kidneys: B2M is small enough to be freely filtered by the glomerulus, and then roughly 99.9% gets reabsorbed and broken down by the tubular cells in the kidney.2PubMed Central. Comparison of Urinary Beta-2 Microglobulin Levels in Children with SSNS and Calcineurin Inhibitor–Treated SRNS This two-part cycle means that blood B2M levels reflect both how fast cells are producing it and how efficiently the kidneys are clearing it. A rise in either production or a drop in kidney clearance pushes the number up.
The Serum Reference Range and How Age Shifts It
Most labs print something like 0.7 to 1.8 mg/L or 1.0 to 2.4 mg/L as their “normal” range, but these numbers depend on the assay method, the population used to set the range, and especially the ages included. A study that specifically investigated healthy adults over 40 found the overall nonparametric reference range was 0.95 to 2.73 mg/L, with a clear upward trend by decade: people aged 40 to 50 fell between about 0.94 and 1.54 mg/L, those 51 to 65 between 0.96 and 2.62 mg/L, and those over 65 between 1.13 and 2.84 mg/L.3PubMed. Value of β2-microglobulin in the serum of healthy subjects older than 40 years An HIV study used a control group whose mean was 1.28 mg/L and listed a normal ceiling of 2.4 mg/L.4PubMed Central. BETA-2-MICROGLOBULIN LEVELS IN HUMAN-IMMUNODEFICIENCY VIRUS INFECTED SUBJECTS
This age-related climb makes sense biologically. Kidney filtration rate declines gradually with age even in people with no kidney disease, so the kidneys clear B2M a bit more slowly. Meanwhile, immune system activity and cell turnover rates change over a lifetime. The practical takeaway is that a B2M of 2.5 mg/L in a 70-year-old might be perfectly unremarkable, while the same number in a 30-year-old would prompt a closer look.
Children sit at different reference points entirely. Newborn B2M runs high, roughly 2.84 to 3.38 mg/L, reflecting the immature kidneys and high cell-turnover rate of early life. Levels drop over the first year and then stabilize at about 1.48 to 1.56 mg/L throughout the rest of childhood.5PubMed. Reference values of beta 2 microglobulin concentrations in the serum of children A pediatric result that looks elevated by adult standards may be perfectly normal for an infant.
Urine and Cerebrospinal Fluid Ranges
Because the kidney reabsorbs almost all filtered B2M, very little should appear in urine. A commonly cited upper limit for normal urine B2M is about 0.3 mg/L.2PubMed Central. Comparison of Urinary Beta-2 Microglobulin Levels in Children with SSNS and Calcineurin Inhibitor–Treated SRNS When urine B2M rises above that, it signals tubular damage: the reabsorption machinery in the proximal tubule is not working properly. Urine B2M testing comes with a practical catch, though. The protein degrades quickly in acidic urine, breaking down at a pH below about 5.5 to 6.0 at body temperature. Lab work from the early 1980s showed this instability was likely caused by enzymes in the urine and could be abolished by heating the sample to 80 °C.6PubMed. beta 2-Microglobulin instability in pathological urine In practice, this means your urine sample needs to be alkalinized or kept cold quickly after collection, or the lab may get a falsely low result.
B2M also shows up in cerebrospinal fluid (CSF), where it serves as a marker for inflammation or malignancy inside the central nervous system. Normal CSF B2M sits between about 0.2 and 2.0 mg/L, slightly lower than serum levels. Researchers use the ratio of CSF to blood B2M (called Q-beta-2) to determine whether the protein is simply leaking in from the blood or being produced locally inside the brain. A Q-beta-2 above 1.0 points clearly to production within the central nervous system itself.7PubMed Central. Beta2-Microglobulin as a Diagnostic Marker in Cerebrospinal Fluid: A Follow-Up Study The highest CSF levels in that study appeared in bacterial meningitis and in brain tumors or malignant infiltrations, where tissue destruction and tumor cell activity both drive production up.
CSF B2M is also elevated in viral meningitis. In children over six months of age without meningitis, mean CSF B2M was about 0.84 mg/L, while those with viral meningitis averaged 2.41 mg/L. A cutoff of 1.2 mg/L worked well for distinguishing the two groups.8PubMed. Beta-2-microglobulin and ferritin in cerebrospinal fluid for evaluation of patients with meningitis of different etiologies A 2024 retrospective study in adults confirmed similar findings, concluding that CSF B2M could serve as a biomarker for diagnosing and monitoring viral encephalitis and meningitis.9Clinical Biochemistry. Elevated levels of β2-microglobulin in cerebrospinal fluid in adult patients with viral encephalitis/meningitis
Why Doctors Order B2M for Blood Cancers
Probably the most familiar clinical use of serum B2M is in staging multiple myeloma. Myeloma cells produce and shed large quantities of B2M, and the serum level correlates strongly with how much tumor is present. A landmark prospective study of 160 myeloma patients found that serum B2M tracked closely with total tumor burden at diagnosis, in remission, and at early relapse. Higher levels at each stage predicted shorter survival.10Blood. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment–a prospective study of 160 patients B2M is now baked into the International Staging System (ISS) and its revised version (R-ISS) for myeloma. Patients with B2M below 3.5 mg/L at diagnosis are classified as Stage I and generally have the best outlook; those above 5.5 mg/L land in Stage III. So when your oncologist watches your B2M at follow-up visits, the trajectory matters as much as any single reading.
Researchers have pushed B2M further by looking at how quickly it drops after treatment begins. A 2024 analysis developed a “B2M decline index” and found that patients whose levels fell more steeply during treatment had better overall survival. The decline index was an independent predictor of outcomes even after accounting for ISS stage, whether the patient received a transplant, and other factors.11PubMed Central. Prognostic significance of β2-microglobulin decline index in multiple myeloma In practical terms, a myeloma patient whose B2M is falling quickly is likely responding well to therapy.
Interestingly, not all lymphomas push B2M up. One study of primary mediastinal large cell lymphoma found that even though every patient had bulky disease, only 6% had elevated serum B2M at diagnosis.12PubMed. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase This is a reminder that B2M behaves differently across cancer types. A normal B2M does not rule out malignancy in every setting.
Autoimmune Disease and Immune Activation
Any condition that revs up the immune system tends to raise B2M, because more immune cells are dividing and shedding it. Systemic lupus erythematosus (SLE) is one of the best-studied examples. A meta-analysis pooling data from multiple studies found a strong positive correlation between serum B2M and lupus disease activity.13PubMed Central. Correlation between serum β2-microglobulin level and systemic lupus erythematosus disease activity: A PRISMA-compliant meta-analysis Individual studies have filled in the details: one Egyptian cohort found that SLE patients averaged a serum B2M of about 6.4 mg/L, roughly two and a half times the 2.5 mg/L seen in healthy controls. The level correlated with kidney markers like creatinine, urea, and urinary protein.14The Egyptian Rheumatologist. Serum beta2-microglobulin level in systemic lupus erythematosus patients: Relation to disease activity
The kidney connection is particularly important. Lupus nephritis, the kidney inflammation that can accompany SLE, drives B2M up both because the kidneys clear less of it and because inflamed tissue pumps out more. A cross-sectional study found that serum B2M predicted lupus nephritis with a sensitivity above 92% and could also predict overall disease activity and organ damage scores.15PubMed Central. Serum beta-2 microglobulin as a predictor of nephritis, disease activity, and damage score in systemic lupus erythematosus: a cross-sectional study For patients with lupus, rising B2M can be an early warning that the kidneys are getting involved.
HIV and Infectious Disease
B2M was one of the earliest surrogate markers studied in HIV, back when CD4 counts were the only other game in town. Research found that the mean B2M level was 2.69 mg/L in people with asymptomatic HIV infection, 12.14 mg/L in those with persistent generalized lymphadenopathy, and 39.29 mg/L in patients who had progressed to AIDS.4PubMed Central. BETA-2-MICROGLOBULIN LEVELS IN HUMAN-IMMUNODEFICIENCY VIRUS INFECTED SUBJECTS The progressive rise tracked disease progression and immune activation. Modern HIV care relies on viral load testing, which is more precise, but B2M remains useful in resource-limited settings and as an adjunctive marker when viral load alone does not tell the full story.
Kidney Disease, Dialysis, and Amyloidosis
Because the kidneys are the main clearance route for B2M, any significant loss of kidney function causes levels to climb. In people on long-term dialysis, the situation becomes extreme: conventional hemodialysis does not remove B2M efficiently, so it accumulates over years. This chronic buildup leads to a condition called dialysis-related amyloidosis (DRA), in which B2M proteins misfold and deposit as amyloid fibrils in bones, joints, and the carpal tunnel.16PubMed Central. Beta-2 Microglobulin Amyloidosis: Past, Present, and Future DRA was first described almost half a century ago and remains a significant source of joint pain and functional disability in long-term dialysis patients. Older age at the start of dialysis and longer time on dialysis are the two biggest risk factors.17Journal of the American Society of Nephrology. Beta 2-microglobulin amyloidosis in chronic dialysis patients: a case report and review of the literature
The amyloid deposits are not just B2M alone. Elevated plasma B2M sets the stage, but the actual damage involves a cast of other molecules: proteins modified by advanced glycation end products, calcium crystals, cytokines, and changes to collagen and other connective tissue.18PubMed. Beta2-microglobulin and amyloidosis High-flux dialysis membranes and online hemodiafiltration do a better job of removing B2M, and these newer techniques have reduced the incidence of DRA compared with older dialysis methods.
Even outside the dialysis setting, urine B2M serves as a marker for tubular injury. A study of patients recovering from acute kidney injury found that over 70% still had urine B2M levels above the 95th percentile of healthy controls at their first follow-up visit, and about half remained elevated months later.19PubMed Central. Short-term Changes in Urine Beta 2 Microglobulin Following Recovery of Acute Kidney Injury Resulting From Snake Envenomation That persistence suggests ongoing tubular dysfunction even after creatinine returns to normal.
B2M as a Kidney Function Estimator
Researchers have tried to use serum B2M as an alternative to creatinine for estimating how well the kidneys are filtering. In critically ill children, B2M correlated better with measured kidney filtration than creatinine did, and its ability to detect reduced filtration was comparable to cystatin C, another small-protein marker.20PubMed Central. Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children However, the picture is less rosy when B2M-based equations are tested against the standard creatinine-based formulas in general chronic kidney disease populations. A Chinese study found that the B2M-based equation performed worse than established creatinine-based formulas in most outcomes.21PubMed Central. Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study B2M is influenced by inflammation, immune activation, and malignancy as well as kidney function, so it is a “noisier” signal than creatinine for pure filtration estimation. It remains most useful as a complementary marker, especially in populations where creatinine itself is unreliable, such as patients with very low muscle mass.
When Low B2M Is the Problem
Most clinical attention focuses on elevated B2M, but unusually low levels can also carry meaning. A study of elderly adults found that a serum B2M below about 2.26 mg/L was associated with over ten times the odds of sarcopenia, the age-related loss of muscle mass and strength. At that cutoff, the test had sensitivity above 92% and specificity above 80% for identifying sarcopenic patients.22PubMed Central. Low Serum Beta-2 Microglobulin Level: A Possible Biomarker for Sarcopenia in the Elderly Population The proposed explanation is straightforward: sarcopenic patients tend to be malnourished and have suppressed immune activity, which reduces B2M production.
A similar pattern appeared in peritoneal dialysis patients. Those in the lowest third of B2M levels had worse survival, particularly among new dialysis patients who still had some remaining kidney function. The authors suggested that very low B2M in this context reflects poor nutrition and a weakened immune system, leaving patients vulnerable to infections.23Nephrology Dialysis Transplantation. Lower serum beta-2 microglobulin levels are associated with worse survival in incident peritoneal dialysis patients This is a useful reminder that B2M is not a one-directional alarm. The number has to be read in context: high can be bad, but unexpectedly low in someone who “should” have a higher reading also deserves attention.
How Pregnancy Alters the Numbers
Pregnant women follow a distinctive B2M trajectory. Blood levels dip early in pregnancy, reaching a minimum around week 14, and then rise steadily, peaking near week 34.24PubMed. Circulating beta-2-microglobulin levels during pregnancy and their possible relationship with feto-maternal histocompatibility Pooled data across studies show maternal B2M dropping from a non-pregnant baseline of about 1.53 mg/L to roughly 1.35 mg/L at 15 weeks, then climbing to approximately 2.03 mg/L by 40 weeks.25Journal of Pharmacology and Clinical Toxicology. Integration of Existing Data on the Utility of Beta-2-Microglobulin during Human Pregnancy as a Biomarker of Fetal Renal Function Development The early dip likely reflects the expansion of blood volume and increased kidney filtration rate in the first trimester, while the late rise tracks with the growing fetal contribution of B2M entering the maternal circulation. Fetal urine B2M, estimated from neonatal urine collected shortly after delivery, decreases through the second half of pregnancy as the fetal kidneys mature and begin reabsorbing the protein more efficiently. Researchers have explored using amniotic-fluid and maternal B2M as a window into fetal kidney development, though this application remains largely investigational.
For clinicians interpreting B2M results in a pregnant patient, the key point is that a mildly elevated value in the third trimester may be physiologically normal and should not automatically trigger concern about kidney disease or malignancy.
Practical Tips for Interpreting Your Result
If you are looking at a B2M result on a lab report, a few things are worth keeping in mind. First, always compare your number to the reference range printed on that specific report, not a number you found online. Different labs use different assays, and the normal range can shift by a few tenths of a mg/L depending on the method. Second, a single borderline result in isolation rarely means much. B2M can spike temporarily with any viral illness, because immune activation ramps up production. Your doctor will usually want to see the trend over time or pair B2M with other tests before drawing conclusions.
Third, if you are being tested for kidney function rather than cancer, expect your doctor to interpret B2M alongside creatinine and possibly cystatin C. B2M alone is too easily swayed by non-kidney factors to stand as a solo kidney marker. And if you are providing a urine sample specifically for B2M, ask whether the lab needs special handling: acidic urine can destroy the protein before it reaches the analyzer, leading to misleadingly low results.6PubMed. beta 2-Microglobulin instability in pathological urine Some labs add a buffer to the collection container or instruct you to keep the sample refrigerated to prevent degradation.